Developing precision medicines for kidney diseases

Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases.

Read More

News & HIGHLIGHTs

Visit our news page for the latest press releases

Read More

August 12, 2021

Download the latest Chinook Corporate Presentation

Read More

Atrasentan Update

The atrasentan phase 3 ALIGN clinical trial is enrolling patients with IgA nephropathy and the atrasentan phase 2 AFFINITY clinical trial is enrolling patients with proteinuric glomerular diseases.

Read More

Pipeline

Advancing a pipeline of precision medicines for kidney diseases.

Our lead pipeline candidates target rare, severe kidney disorders with few currently approved therapies.

pipeline

mobile pipeline

Learn More